Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma

Xiaofen Li,1,2,* Xia Li,3,* Xuefeng Fang,1 Ying Yuan1 1Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; 2Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; 3Department of Operation Room, Zhejiang Province People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China *These authors contributed equally to this work Abstract: To date, there is no standard third-line therapy for EGFR- and ALK-negative lung squamous cell carcinoma (SCC). Apatinib, an oral small-molecule VEGFR-2 inhibitor, has shown good therapeutic effect and safety in chemotherapy-refractory gastric cancer, but its efficacy in lung SCC is not determined. In this report, we present a 69-year-old Chinese man with locally advanced EGFR- and ALK-negative lung SCC, who received apatinib after failure of 2 treatment regimens. After 4 months of apatinib therapy, chest computed tomography scan showed a large cavity in the lung tumor, while there was minimal change in tumor size. The patient had quite a long progression-free survival time of over 17 months and tolerated apatinib very well. Apatinib provides an additional option for salvage treatment of lung SCC without driver gene mutations, but further large-scale clinical studies are still warranted. Keywords: apatinib, lung squamous cell carcinoma, efficac